Current research on respiratory viral infections: Fifth International Symposium1

Ison, Michael G.; Johnston, Sebastian L.; Openshaw, Peter; Murphy, Brian R.; Hayden, Frederick G.

doi:10.1016/j.antiviral.2003.12.006

Cited by 7 publications

(2 citation statements)

References 143 publications

(135 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, these titers did not persist so that annual vaccination would be necessary to maintain potentially protective antibody titers with this candidate vaccine. 43 BBG2Na (Pierre Fabre, Castres, France), a promising vaccine candidate that was developed by fusing the conserved central domain of the RSV G protein to the albumin-binding region of streptococcal protein G, was found to be safe and immunogenic in phase 1 and phase 2 studies, but unexpected side-effects in the phase 3 trial (purpura / type III hypersensitivity) in a small number of vaccine recipients halted further development. 38 Live Attenuated Respiratory Syncytial Virus Vaccines Several live attenuated RSV vaccines were developed by passage of RSV at increasingly lower temperatures (cold passage, cp) and by chemical mutagenesis, and temperature-sensitive (ts) and non-ts attenuating mutations were identified.…”

Section: Inactivated and Subunit Respiratory Syncytial Virus Vaccinesmentioning

confidence: 99%

Progress in Respiratory Virus Vaccine Development

Schmidt¹

2007

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Viral respiratory infections continue to cause significant morbidity and mortality in infants and young children as well as in at-risk adults and the elderly. Although many viral pathogens are capable of causing acute respiratory disease, vaccine development has to focus on a limited number of pathogens (i.e., agents that commonly cause serious lower respiratory disease). Inactivated and, more recently, live attenuated influenza virus vaccines are the mainstay of interpandemic influenza prevention, but vaccines are not available yet for other important viruses such as respiratory syncytial virus, metapneumovirus, the parainfluenza viruses, and avian influenza viruses with pandemic potential. Reverse genetics systems that allow rational vaccine development are now widely used, and considerable progress has been made in preclinical and clinical development of novel respiratory virus vaccines.

show abstract

Section: Inactivated and Subunit Respiratory Syncytial Virus Vaccinesmentioning

confidence: 99%

Progress in Respiratory Virus Vaccine Development

Schmidt¹

2007

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…This vaccine is well tolerated, induces neutralizing antibody responses in healthy young adults, and is immunogenic in elderly individuals. Finally, subunit vaccines containing copurified F, G, and M proteins formulated with an alum adjuvant are being investigated [38,48]. However, the likely targets for these vaccines will be elderly adults and those at high risk for severe RSV infection.…”

Section: Prevention Of Respiratory Syncytial Virus Disease: Active Immentioning

confidence: 99%

The Cell Biology of Acute Childhood Respiratory Disease: Therapeutic Implications

Loughlin

Moscona

2006

Pediatric Clinics of North America

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV), the recently identified human metapneumovirus (HMPV), and the human parainfluenza viruses (HPIVs), cause most cases of childhood croup, bronchiolitis, and pneumonia. Influenza virus also causes a significant burden of disease in young children, although its significance in children was not fully recognized until recently. This article discusses pathogens that have been studied for several decades, including RSV and HPIVs, and also explores the newly identified viral pathogens HMPV and human coronavirus NL63. The escalating rate of emergence of new infectious agents, fortunately meeting with equally rapid advancements in molecular methods of surveillance and pathogen discovery, means that new organisms will soon be added to the list. A section on therapies for bronchiolitis addresses the final common pathways that can result from infection with diverse pathogens, highlighting the mechanisms that may be amenable to therapeutic approaches. The article concludes with a discussion of the overarching impact of new diagnostic strategies.

show abstract

Upper Respiratory Tract Infection

Heikkinen

Ruuskanen

2006

Encyclopedia of Respiratory Medicine

View full text Add to dashboard Cite

Current research on respiratory viral infections: Fifth International Symposium1

Cited by 7 publications

References 143 publications

Progress in Respiratory Virus Vaccine Development

Progress in Respiratory Virus Vaccine Development

The Cell Biology of Acute Childhood Respiratory Disease: Therapeutic Implications

Upper Respiratory Tract Infection

Contact Info

Product

Resources

About